Here’s the real lesson for investors about Donald Trump’s victory. Read More
John Persinos is the editorial director of Investing Daily, overseeing such publications as Personal Finance, Utility Forecaster, Profit Catalyst Alert, Rapier's Income Accelerator, Income Forecaster, and Marijuana Investing Daily, among others. John also writes the Mind Over Markets daily stock market recap, and he's the chief investment strategist of Marijuana Profit Alert.
John has decades of experience in the technology and political realms. He has worked as a staff editor at Inc. and Venture magazines, and written for Kiplinger's, Street Authority, Investing Answers, and TheStreet.com, to name a few. In a career that has spanned more than 40 years, John has been diligently and prolifically covering the news and its impact on investors.
John also has experience with the inner-workings of Capitol Hill, serving as a press secretary to U.S. Rep. Byron Dorgan (D-ND). John started his career as a daily newspaperman with The Orlando Sentinel.
John holds undergraduate and graduate degrees from Boston University. He also completed the Davenport Fellowship in Business and Economics Reporting at the University of Missouri (Columbia).
Analyst Articles
We all know the expression that a fool and his money are soon parted. But as we observe the irrational actions of energy traders lately, it begs the question: How did these fools and their money get together in the first place?Case in point: The irrational exuberance now bidding up the… Read More
Steve Jobs once said that he wanted to “make a dent in the universe.” The legendary founder and CEO of Apple (NASDAQ: AAPL) certainly dinged the cosmos, by creating astonishing products that transformed our lives. In the process, he helped make a lot of people rich. Since Apple went public… Read More
As we discussed yesterday, the math behind “asymmetric” investing is compelling… Perhaps the sector that’s most illustrative of its effectiveness is biotechnology. Let’s consider a hypothetical portfolio comprised of three well-known Big Pharma stocks: Pfizer (NYSE: PFE), Merck (NYSE: MRK), and Abbott Laboratories (NYSE: ABT). Scrutinizing their fundamentals (balance… Read More
Oil prices are plunging and yet solar power continues to thrive. We explain the dynamics behind solar’s inexorable rise Read More
This leader in satellite technology will continue to fly above its competitors, as demand soars for space-based imagery. Read More
This global drug maker is paving the way for long-term gains by targeting rare diseases. Read More
We respond to recurring reader queries regarding their 401k plans. Read More
Here's how to choose the right mix of assets for your long-term retirement goals. Read More
As China exploits its unconventional oil and gas reserves, this leading oilfield services provider is positioned for outsized gains. Read More